Erratum to: Role of Pharmacologic Paralysis in Acute Respiratory Distress Syndrome

Authors have informed the Publisher about an error in the above-mentioned article published in volume 40, issue 1 of the journal SRCCM. DOI of the original article: 10.1055/s-0039-1683883.

One randomized trial was inadvertently not included in this review. This trial, published in 2017, randomized 24 ARDS patients with a P/F < 150 and a PEEP ≥ 5 cm H₂O, in two French ICUs, to a cisatracurium infusion for 48 hours or not (control group). All patients were monitored with an esophageal catheter and multiple respiratory mechanic and oxygenation metrics were measured over 48 hours. The authors found improved oxygenation, lower plateau pressure and total PEEP, and higher inspiratory and expiratory transpulmonary pressures, in the cisatracurium group versus the control group. The authors apologize for the omission.

Corrected table is as follows:

Table 3 Randomized trials of neuromuscular blockade in acute respiratory distress syndrome^24-28 (Note that these refs don't cover the 2017 trial)

Trial	N	No. of hospitals	Primary findings	Year
Gainnier et al	56	4	Improved oxygenation	2004
Forel et al	36	3	Decreased pulmonary and serum pro-inflammatory cytokine levels	2006
ACURASYS	340	20	Improved adjusted 90-d survival, with no difference in muscle weakness	2010
Lyu et al	96	1	Improved physiologic indices and 21-d survival, in severe ARDS	2014
Guervilly et al	24	2	Improved respiratory mechanics	2017[a]
ROSE	1,006	48	Pending	Enrollment completed 2018

Abbreviations: ACURASYS, ARDS et Curarisation Systematique; ARDS, acute respiratory distress syndrome; ROSE, Reevaluation Of Systemic Early neuromuscular blockade.

Note: Except for two trials, each trial randomized patients to cisatracurium for 48 hours versus placebo, and enrolled acute respiratory distress syndrome patients with a P/F < 150. (The Lyu et al trial tested vecuronium. The Forel et al and Lyu et al trials used a P/F < 200.)

^a The reference for the 2017 trial is Guervilly C, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Randomized controlled trial. Intensive Care Med 2017;43(3):408–418.